Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: Citrulline-dependent or not?

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 511-516

  Vannini, A ^a   Cheung, K ^b   Fusconi, M ^c   Stammen Vogelzangs, J ^b   Drenth, J P H ^d   Dall'Aglio, A C ^a   Bianchi, F B ^a   Bakker Jonges, L E ^e   Van Venrooij, W J ^b   Pruijn, G J M ^b   Zendman, A J W ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHILD; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; REAGENT KITS, DIAGNOSTIC; RHEUMATIC DISEASES;

EID: 34147211618     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058933     Document Type: Article

References (29)

1. Pruijn GJM, Vossenaar ER, Drijfhout JW, van Venrooij WJ, Zendman AJW. Anti-CCP antibody detection facilitates early diagnosis and prognosis of rheumatoid arthritis. Curr Rheum Rev 2005;1:1-7.
2. Zendman AJW, Vossenaar ER, van Venrooij WJ. Autoantibodies to citrullinated (poly) peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004;37:295-9.
3. Vossenaar ER, Zendman AJW, van Venrooij WJ, Pruijn GJM. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003;25:1106-18.
4. van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6:37-41.
5. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
6. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
7. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67-8.
8. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
9. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
11. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677-83.
12. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
13. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824.
14. Loukili NH, Pettorin C, Noel E, Andres E. Type 1 autoimmune hepatitis revealed by a dysphonia related to cricoarytenoid arthritis. Q J Med 2003;96:171-2.
15. Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 2002;37:617-25.
16. Fusconi M, Vannini A, Dall'aglio AC, Pappas G, Cassani F, Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22:951-5.
17. Yonder Cruyssen B, Hoffman IE, Zmierczak H, van den Berghe M, Kruithof E, de Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.
18. Alenius GM, Berglin E, Rantapaa-Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without manifestation of joint inflammation. Ann Rheum Dis 2006;65:398- 400.
19. Salvador G, Gomez A, Vinas O, Ercilla G, Canete JD, Munoz-Gomez J, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) 2003;42:972-5.
20. Ingegnoli F, Galbiati V, Zeni S, Meani L, Zahalkova L, Lubatti C, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol, in press.
21. Gottenberg JE, Mignot S, Nicaise-Rolbnd P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti- keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2004;64:114-17.
22. Hoffman IE, Peene I, Cebecauer L, Isenberg D, Huizinga TW, Union A, et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005;64:330-2.
23. Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, et al. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1. Biomedica 2004;24:140-52.
24. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002;60:383-8.
25. Vossenaar ER, van Boekel MA, van Venrooij WJ, Lopez-Hoyoz M, Merino J, Merino R, et al. Absence of citrulline-specific autoantibodies in animal models of autoimmunity. Arthritis Rheum 2004;50:2370-2.
26. Luxon BA. Autoimmune hepatitis. Making sense of all those antibodies. Postgrad Med 2003;114:79-8.
27. Strassburg CP, Manns MP. Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:585-99.
28. Bianchi FB, Muratori L. Primary and secondary autoimmunity in hepatology. Ann Ital Med Int 2000;15:56-62.
29. Garcia-Berrocal B, Gonzalez C, Perez M, Navajo JA, Moreta I, Davila C, et al. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients. Clin Chim Acta 2005;354:123- 30.